Actions of Trace Amines in the Brain-Gut-Microbiome Axis via Trace Amine-Associated Receptor-1 (TAAR1).

Trace amines and their primary receptor, Trace Amine-Associated Receptor-1 (TAAR1) are widely studied for their involvement in the pathogenesis of neuropsychiatric disorders despite being found in the gastrointestinal tract at physiological levels. With the emergence of the "brain-gut-microbiome axis," we take the opportunity to review what is known about trace amines in the brain, the defined sources of trace amines in the gut, and emerging understandings on the levels of trace amines in various gastrointestinal disorders. Similarly, we discuss localization of TAAR1 expression in the gut, novel findings that TAAR1 may be implicated in inflammatory bowel diseases, and the reported comorbidities of neuropsychiatric disorders and gastrointestinal disorders. With the emergence of TAAR1 specific compounds as next-generation therapeutics for schizophrenia (Roche) and Parkinson's related psychoses (Sunovion), we hypothesize a therapeutic benefit of these compounds in clinical trials in the brain-gut-microbiome axis, as well as a potential for thoughtful manipulation of the brain-gut-microbiome axis to modulate symptoms of neuropsychiatric disease.

Trace amine associated receptor 1 (TAAR1) expression and modulation of inflammatory cytokine production in mouse bone marrow-derived macrophages: a novel mechanism for inflammation in ulcerative colitis.

Context: Tissue resident macrophages and peripherally infiltrating macrophages play a prominent role in maintaining homeostasis in the gastrointestinal tract (GIT), though aberrant activation is implicated in inflammatory conditions, including ulcerative colitis (UC). Recent metabolomic studies indicate that tyramine (TYR) is elevated in the stool of patients with UC. TYR activates the mammalian trace amine associated receptor 1 (TAAR1). Our previous work identified TAAR1 expression in mixed populations of immune cells, whereas a limited number of other studies have identified TAAR1-dependent effects in cytokine secretion and gene expression in T-cells and B-cells.Objective: To investigate whether TAAR1 may serve as a novel target for an anti-inflammatory therapeutic in UC, we explored TAAR1 expression in mouse bone marrow-derived macrophages (BMDMs), and its upregulation and activation in response to LPS and TYR.Results: Here, we demonstrate for the first time that TAAR1 is expressed in BMDM and undergoes agonist-induced upregulation. Additionally, TYR elicits significant increases in inflammatory cytokine gene expression in non-polarized and LPS-polarized BMDM, and the TAAR1 antagonist EPPTB inhibits the TYR-mediated upregulation of TAAR1 and inflammatory cytokine gene expression in BMDM. Conclusions: Our data suggest that TAAR1 is a mediator of macrophage inflammation and a potential therapeutic target to attenuate UC symptomology.